OBJECTIVE: The objective of this study was to screen and identify differentially expressed genes in invasive bladder transitional cell carcinoma (BTCC). METHODS: Voided urine samples were collected from consecutive patients with BTCC and patients under surveillance for bladder cancer recurrence; voided urine samples from patients with non-malignant diseases served as control. We identified the differentially expressed genes by comparing urine samples of bladder carcinoma to that of the control group with suppressive subtractive hybridization (SSH) and cDNA microarray. The differentially expressed genes were verified by quantitative real-time polymerase chain reaction (QPCR). RESULTS: From the 762 white colonies, a total of 449 positive clones were obtained in which 112 were found to be upregulated in BTCC. Sequencing and homology analysis were performed for these 112 clonies. The detection rates of some known genes (including IGF-1, human telomerase reverse transcriptase [hTERT], bladder cancer specific nuclear matrix protein 4 [BLCA-4] and homeobox A13 [HOXA13]) for BTCC at the Ta, T1 and >T1 stages were 48%, 90% and 100%, respectively, with a specificity of 85%. The test specificity was 80% for the 30 control patients with urinary tract infections. The combination of BLCA-4 and HOXA13 could distinguish between low- and high-grade tumours, with specificity and sensitivity of 80%. CONCLUSION: We successfully constructed a reliable SSH library of BTCC and found that combination detection insulin-like growth factor 1 (IGF-1), hTERT, BLCA-4 and HOXA13 genes could help to evaluate BTCC at different stages.
OBJECTIVE: The objective of this study was to screen and identify differentially expressed genes in invasive bladder transitional cell carcinoma (BTCC). METHODS: Voided urine samples were collected from consecutive patients with BTCC and patients under surveillance for bladder cancer recurrence; voided urine samples from patients with non-malignant diseases served as control. We identified the differentially expressed genes by comparing urine samples of bladder carcinoma to that of the control group with suppressive subtractive hybridization (SSH) and cDNA microarray. The differentially expressed genes were verified by quantitative real-time polymerase chain reaction (QPCR). RESULTS: From the 762 white colonies, a total of 449 positive clones were obtained in which 112 were found to be upregulated in BTCC. Sequencing and homology analysis were performed for these 112 clonies. The detection rates of some known genes (including IGF-1, human telomerase reverse transcriptase [hTERT], bladder cancer specific nuclear matrix protein 4 [BLCA-4] and homeobox A13 [HOXA13]) for BTCC at the Ta, T1 and >T1 stages were 48%, 90% and 100%, respectively, with a specificity of 85%. The test specificity was 80% for the 30 control patients with urinary tract infections. The combination of BLCA-4 and HOXA13 could distinguish between low- and high-grade tumours, with specificity and sensitivity of 80%. CONCLUSION: We successfully constructed a reliable SSH library of BTCC and found that combination detection insulin-like growth factor 1 (IGF-1), hTERT, BLCA-4 and HOXA13 genes could help to evaluate BTCC at different stages.
Authors: Lars Dyrskjøt; Thomas Thykjaer; Mogens Kruhøffer; Jens Ledet Jensen; Niels Marcussen; Stephen Hamilton-Dutoit; Hans Wolf; Torben F Orntoft Journal: Nat Genet Date: 2002-12-09 Impact factor: 38.330
Authors: Thu-Suong Van Le; Raymond Miller; Timothy Barder; Marko Babjuk; Douglas M Potter; Robert H Getzenberg Journal: Urology Date: 2005-12 Impact factor: 2.649
Authors: Peter J Wild; Alexander Herr; Christoph Wissmann; Robert Stoehr; Andre Rosenthal; Dirk Zaak; Ronald Simon; Ruth Knuechel; Christian Pilarsky; Arndt Hartmann Journal: Clin Cancer Res Date: 2005-06-15 Impact factor: 12.531
Authors: Lars Dyrskjøt; Karsten Zieger; Mogens Kruhøffer; Thomas Thykjaer; Jens L Jensen; Hanne Primdahl; Natasha Aziz; Niels Marcussen; Klaus Møller; Torben F Orntoft Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Neeraja L Varanasi; Inthumathi Baskaran; George J Alangaden; Pranatharthi H Chandrasekar; Elias K Manavathu Journal: Int J Antimicrob Agents Date: 2004-01 Impact factor: 5.283